DDInter133 DDInter1652
Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid. This conversion is a critical metabolic reaction involved in the production of several compounds involved in lipid metabolism and transport, including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very-low-density lipoprotein (VLDL). Prescribing statins is considered standard practice for patients following any cardiovascular event, and for people who are at moderate to high risk of developing cardiovascular disease. The evidence supporting statin use, coupled with minimal
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Atorvastatin {u} (Compound) resembles {v} (Compound) Conivaptan
Atorvastatin {u} (Compound) treats {v} (Disease) coronary artery disease
Atorvastatin {u} (Compound) binds {v} (Gene) SLCO1B3
Atorvastatin {u} (Compound) upregulates {v} (Gene) PRKCD
Atorvastatin {u} (Compound) downregulates {v} (Gene) CCDC86
Atorvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Medroxyprogesterone acetate
Atorvastatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Aluminum hydroxide
Atorvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etoposide
Atorvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Atorvastatin {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Atorvastatin (Compound) resembles Conivaptan (Compound)
Atorvastatin (Compound) treats coronary artery disease (Disease)
Atorvastatin (Compound) binds SLCO1B3 (Gene)
Atorvastatin (Compound) upregulates PRKCD (Gene)
Atorvastatin (Compound) downregulates CCDC86 (Gene)
Atorvastatin may cause a minor interaction that can limit clinical effects when taken with Medroxyprogesterone acetate
Atorvastatin may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Atorvastatin may lead to a major life threatening interaction when taken with Leflunomide